Education
About Us
Working with TipRanks
Follow Us
Ocular Therapeutix (OCUL)
NASDAQ:OCUL
OCUL Analyst Ratings
Strong Buy
11 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
OCUL Stock 12 Month Forecast
Average Price Target
$22.70
▲(82.62% Upside)
| Highest Price Target$31.00 | Average Price Target$22.70 | Lowest Price Target$18.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Piper Sandler
$31
Buy
149.40%
Upside
Reiterated
12/05/25
H.C. Wainwright
$19
Buy
52.86%
Upside
Reiterated
11/25/25
William Blair
―
Buy
―
Reiterated
11/24/25
Wall Street Analysts Are Bullish on Top Healthcare PicksWe believe Ocular’s lead asset, Axpaxli, has the potential to represent a significant advance in the treatment of wet AMD, and believe the top-line readout from the Phase III SOL-1 study in the first quarter of2026 will be a major catalyst for the stock. In addition, with randomization for SOL-R now complete, we expect top-line data in the first half of 2027. This timeline continues to support a potential approval as early as late 2027. In the meantime, we view the rapid initiation of the HEALIOS studies as another sign of strong execution as the company looks to expand the potential for Axpaxli across retinal diseases. We see blockbuster potential for Axpaxli in wet AMD alone and rate shares Outperform.
TD Cowen
$20
Buy
60.90%
Upside
Reiterated
11/04/25
Ocular Therapeutix's Strategic Positioning and High Success Probability Support Buy RatingWe therefore view the absolute delta and other data points of focus (i.e. absolute letters lost) as largely irrelevant in the event of the trial being successful. That being said, if given the option of a very large delta with little to no secondary evidence that supports SOL-R read-through, or the alternative of a smaller delta accompanied by secondary results that make SOL-R success even clearer, the favorability of the latter is plain as day.
Needham
$20
Buy
60.90%
Upside
Reiterated
11/04/25
Clear Street
$18→$21
Buy
68.95%
Upside
Reiterated
11/04/25
RBC Capital
$17→$24
Buy
93.08%
Upside
Reiterated
11/04/25
Robert W. Baird
$17→$24
Buy
93.08%
Upside
Reiterated
10/03/25
Citizens JMP
$20→$29
Buy
133.31%
Upside
Reiterated
10/01/25
Bank of America Securities
$18
Buy
44.81%
Upside
Reiterated
10/01/25
Chardan Capital
$21
Buy
68.95%
Upside
Initiated
09/15/25
Scotiabank
$22→$20
Buy
60.90%
Upside
Reiterated
08/06/25
Raymond James
$19
Buy
52.86%
Upside
Reiterated
08/04/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Piper Sandler
$31
Buy
149.40%
Upside
Reiterated
12/05/25
H.C. Wainwright
$19
Buy
52.86%
Upside
Reiterated
11/25/25
William Blair
―
Buy
―
Reiterated
11/24/25
Wall Street Analysts Are Bullish on Top Healthcare PicksWe believe Ocular’s lead asset, Axpaxli, has the potential to represent a significant advance in the treatment of wet AMD, and believe the top-line readout from the Phase III SOL-1 study in the first quarter of2026 will be a major catalyst for the stock. In addition, with randomization for SOL-R now complete, we expect top-line data in the first half of 2027. This timeline continues to support a potential approval as early as late 2027. In the meantime, we view the rapid initiation of the HEALIOS studies as another sign of strong execution as the company looks to expand the potential for Axpaxli across retinal diseases. We see blockbuster potential for Axpaxli in wet AMD alone and rate shares Outperform.
TD Cowen
$20
Buy
60.90%
Upside
Reiterated
11/04/25
Ocular Therapeutix's Strategic Positioning and High Success Probability Support Buy RatingWe therefore view the absolute delta and other data points of focus (i.e. absolute letters lost) as largely irrelevant in the event of the trial being successful. That being said, if given the option of a very large delta with little to no secondary evidence that supports SOL-R read-through, or the alternative of a smaller delta accompanied by secondary results that make SOL-R success even clearer, the favorability of the latter is plain as day.
Needham
$20
Buy
60.90%
Upside
Reiterated
11/04/25
Clear Street
$18→$21
Buy
68.95%
Upside
Reiterated
11/04/25
RBC Capital
$17→$24
Buy
93.08%
Upside
Reiterated
11/04/25
Robert W. Baird
$17→$24
Buy
93.08%
Upside
Reiterated
10/03/25
Citizens JMP
$20→$29
Buy
133.31%
Upside
Reiterated
10/01/25
Bank of America Securities
$18
Buy
44.81%
Upside
Reiterated
10/01/25
Chardan Capital
$21
Buy
68.95%
Upside
Initiated
09/15/25
Scotiabank
$22→$20
Buy
60.90%
Upside
Reiterated
08/06/25
Raymond James
$19
Buy
52.86%
Upside
Reiterated
08/04/25
Best Analysts Covering Ocular Therapeutix
1 Month
xxx
Success Rate
10/21 ratings generated profit
Average Return
+6.66%
reiterated a xxx
rating 11 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 47.62% of your transactions generating a profit, with an average return of +6.66% per trade.
3 Months
xxx
Success Rate
18/30 ratings generated profit
Average Return
+13.02%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +13.02% per trade.
1 Year
Success Rate
22/30 ratings generated profit
Average Return
+46.28%
reiterated a buy rating 2 months ago
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 73.33% of your transactions generating a profit, with an average return of +46.28% per trade.
2 Years
xxx
Success Rate
30/30 ratings generated profit
Average Return
+109.28%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +109.28% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
OCUL Analyst Recommendation Trends
Rating
Jul 25
Aug 25
Sep 25
Oct 25
Nov 25
Strong Buy
13
4
4
13
16
Buy
2
7
7
8
3
Hold
8
5
3
7
8
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
23
16
14
28
27
Each month's total comprises the sum of three months' worth of ratings.
OCUL Financial Forecast
OCUL Stock Forecast FAQ
What is OCUL’s average 12-month price target, according to analysts?
Based on analyst ratings, Ocular Therapeutix’s 12-month average price target is 22.70.
What is OCUL’s upside potential, based on the analysts’ average price target?
Ocular Therapeutix has 82.62% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is OCUL a Buy, Sell or Hold?
Ocular Therapeutix has a consensus rating of Strong Buy which is based on 11 buy ratings, 0 hold ratings and 0 sell ratings.
What is Ocular Therapeutix’s price target?
The average price target for Ocular Therapeutix is 22.70. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $31.00 ,the lowest forecast is $18.00. The average price target represents 82.62% Increase from the current price of $12.43.
The highest analyst price target is $31.00 ,the lowest forecast is $18.00. The average price target represents 82.62% Increase from the current price of $12.43.
What do analysts say about Ocular Therapeutix?
Ocular Therapeutix’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.
How can I buy shares of OCUL?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.